15-Deoxy-Δ12,14-prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factors

Biochemical Pharmacology

Volumn 72, Issue 11, 2006, Pages 1516-1528

  Kim, Eun Hee ^a   Surh, Young Joon ^a  

^a Seoul National University   (South Korea)

Author keywords

15 Deoxy 12,14 prostaglandin; AP 1; NF B; Nrf2; PPAR ; Redox regulation; Thiol modification; Transcription factors

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CYCLOOXYGENASE 2; CYCLOPENTANONE DERIVATIVE; CYTOKINE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; STAT PROTEIN; THIOL GROUP; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; BIOLOGICAL RESPONSE MODIFIER; CYSTEINE; DRUG DERIVATIVE; PROSTAGLANDIN D2;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL FUNCTION; CELL PROTECTION; CONCENTRATION (PARAMETERS); HUMAN; MICHAEL ADDITION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; OXIDATION REDUCTION REACTION; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; ANIMAL; GENE EXPRESSION; METABOLISM; REVIEW; SIGNAL TRANSDUCTION; SOCIAL CONTROL;

ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; CYSTEINE; GENE EXPRESSION; HUMANS; OXIDATION-REDUCTION; PPAR GAMMA; PROSTAGLANDIN D2; SIGNAL TRANSDUCTION; SOCIAL CONTROL, FORMAL; TRANSCRIPTION FACTORS;

EID: 33750530167     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.07.030     Document Type: Article

References (114)

1. Smith W.L. The eicosanoids and their biochemical mechanisms of action. Biochem J 259 (1989) 315-324
2. Straus D.S., and Glass C.K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21 (2001) 185-210
3. 2: the anti-inflammatory prostaglandin?. Clin Immunol 114 (2005) 100-109
4. Na H.K., and Surh Y.J. Peroxisome proliferator-activated receptor γ (PPARγ) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol 66 (2003) 1381-1391
5. Na H.K., and Surh Y.J. Transcriptional regulation via cysteine thiol modification: a novel molecular strategy for chemoprevention and cytoprotection. Mol Carcinog (2006)
6. 2 and the unambiguous assignment of the C14 stereochemistry. Org Lett 6 (2004) 149-152
7. Kondo M., Oya-Ito T., Kumagai T., Osawa T., and Uchida K. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J Biol Chem 276 (2001) 12076-12083
8. Vosseler C.A., Erl W., and Weber P.C. Structural requirements of cyclopentenone prostaglandins to induce endothelial cell apoptosis. Biochem Biophys Res Commun 307 (2003) 322-326
9. Kim E.H., Kim D.H., Na H.K., and Surh Y.J. Effects of cyclopentenone prostaglandins on the expression of heme oxygenase-1 in MCF-7 cells. Ann N Y Acad Sci 1030 (2004) 493-500
10. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA 97 (2000) 4844-4849
11. 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. J Biol Chem 276 (2001) 35530-35536
12. 2. J Biol Chem 278 (2003) 51251-51260
13. 2 in activated murine macrophages. Mol Cell Biol 20 (2000) 1692-1698
14. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403 (2000) 103-108
15. Shibata T., Yamada T., Ishii T., Kumazawa S., Nakamura H., Masutani H., et al. Thioredoxin as a molecular target of cyclopentenone prostaglandins. J Biol Chem 278 (2003) 26046-26054
16. Moos P.J., Edes K., Cassidy P., Massuda E., and Fitzpatrick F.A. Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem 278 (2003) 745-750
17. Levonen A.L., Landar A., Ramachandran A., Ceaser E.K., Dickinson D.A., Zanoni G., et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J 378 (2004) 373-382
18. 2. Mol Cell Biol 24 (2004) 36-45
19. 2 binds to and activates H-Ras. Proc Natl Acad Sci USA 100 (2003) 4772-4777
20. Shiraki T., Kamiya N., Shiki S., Kodama T.S., Kakizuka A., and Jingami H. α, β-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ. J Biol Chem 280 (2005) 14145-14153
21. 2 to the PPARγ ligand-binding domain by multi-wavelength global fitting. Biochem J 393 (2006) 749-755
22. 2 in mesangial cells reveals multiple interactions with the cytoskeleton. J Am Soc Nephrol 17 (2006) 89-98
23. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106 (2000) 189-197
24. 2. Biochem Biophys Res Commun 283 (2001) 750-755
25. Fahmi H., Di Battista J.A., Pelletier J.P., Mineau F., Ranger P., and Martel-Pelletier J. Peroxisome proliferator-activated receptor γ activators inhibit interleukin-1β-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum 44 (2001) 595-607
26. Bordji K., Grillasca J.P., Gouze J.N., Magdalou J., Schohn H., Keller J.M., et al. Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) α and γ and retinoid Z receptor in cartilage PPARγ activation modulates the effects of interleukin-1β on rat chondrocytes. J Biol Chem 275 (2000) 12243-12250
27. 2 for induction of human articular chondrocyte apoptosis in arthritis. J Biol Chem 279 (2004) 37939-37950
28. 2 through a histone deacetylase-independent mechanism. Arthritis Rheum 52 (2005) 94-104
29. Li X., Afif H., Cheng S., Martel-Pelletier J., Pelletier J.P., Ranger P., et al. Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage and chondrocytes. J Rheumatol 32 (2005) 887-895
30. Wayman N.S., Hattori Y., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Pisano B., et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size. FASEB J 16 (2002) 1027-1040
31. 2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 26 (2006) 481-487
32. 2 are associated with good outcome in acute atherothrombotic ischemic stroke. Stroke 36 (2005) 1189-1194
33. 2 ameliorates ischemic acute renal failure. Cardiovasc Res 61 (2004) 630-643
34. Wada K., Nakajima A., and Blumberg R.S. PPARγ and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med 7 (2001) 329-331
35. Su C.G., and Lewis J.D. Antineoplastic and anti-inflammatory effects of PPAR ligands in colitis. Gastroenterology 121 (2001) 1019-1021
36. 2 inhibits G1/S transition and retinoblastoma protein phosphorylation in immortalized lymphocytes from Alzheimer's disease patients. Exp Neurol 195 (2005) 508-517
37. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., and Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 20 (2000) 558-567
38. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
39. Jiang C., Ting A.T., and Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
40. 2 inhibits IL-10 and IL-12 production by macrophages. Biochem Biophys Res Commun 283 (2001) 344-346
41. 2. Proc Natl Acad Sci USA 96 (1999) 4668-4673
42. 2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-κB-p300 pathway independent of peroxisome proliferator-activated receptor γ. J Immunol 173 (2004) 5196-5208
43. 2 is acting as a 'dual agent' on the regulation of COX-2 expression in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 10 (2002) 845-848
44. Inoue H., Tanabe T., and Umesono K. Feedback control of cyclooxygenase-2 expression through PPARγ. J Biol Chem 275 (2000) 28028-28032
45. Subbaramaiah K., Lin D.T., Hart J.C., and Dannenberg A.J. Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 276 (2001) 12440-12448
46. Vichai V., Suyarnsesthakorn C., Pittayakhajonwut D., Sriklung K., and Kirtikara K. Positive feedback regulation of COX-2 expression by prostaglandin metabolites. Inflamm Res 54 (2005) 163-172
47. Adams M.J., and Oostryck R. Further investigations of lupus anticoagulant interference in a functional assay for tissue factor pathway inhibitor. Thromb Res 87 (1997) 245-249
48. Chaput E., Saladin R., Silvestre M., and Edgar A.D. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 271 (2000) 445-450
49. 2: a putative endogenous promoter of adipogenesis suppresses the ob gene. Metabolism 48 (1999) 786-791
50. Soberman R.J., and Christmas P. The organization and consequences of eicosanoid signaling. J Clin Invest 111 (2003) 1107-1113
51. 2 by nuclear factor-κB and other cellular proteins. Bioorg Med Chem Lett 15 (2005) 4057-4063
52. Alarcon de la Lastra C., Sanchez-Fidalgo S., Villegas I., and Motilva V. New pharmacological perspectives and therapeutic potential of PPAR-γ agonists. Curr Pharm Des 10 (2004) 3505-3524
53. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83 (1995) 803-812
54. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83 (1995) 813-819
55. 2 on VEGF synthesis depends on the induction of heme oxygenase-1. Antioxid Redox Signal 4 (2002) 577-585
56. Yuan J., Takahashi A., Masumori N., Uchida K., Hisasue S., Kitamura H., et al. Ligands for peroxisome proliferator-activated receptor γ have potent antitumor effect against human renal cell carcinoma. Urology 65 (2005) 594-599
57. 2 on cell proliferation and apoptosis in ECV304 endothelial cells. Acta Pharmacol Sin 25 (2004) 47-53
58. 2-induced apoptosis in breast cancer cells. J Biol Chem 276 (2001) 47131-47135
59. 2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J Biol Chem 276 (2001) 38152-38158
60. 2 on VEGF in normoxia and hypoxia: role of HIF-1. Biochem Biophys Res Commun 314 (2004) 31-38
61. 2 inhibits IL-6-induced Stat3 phosphorylation in lymphocytes. Exp Mol Med 37 (2005) 179-185
62. 2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res 59 (1999) 2739-2746
63. 2 derivatives really playing the part?. Cell Signal 14 (2002) 573-583
64. 2 addition in mesangial cells: role in the inhibition of pro-inflammatory genes. Mol Pharmacol 66 (2004) 1349-1358
65. Hayes J.D., and McMahon M. The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol Cell 21 (2006) 732-734
66. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13 (1999) 76-86
67. Dinkova-Kostova A.T., Holtzclaw W.D., Cole R.N., Itoh K., Wakabayashi N., Katoh Y., et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99 (2002) 11908-11913
68. Lee J.S., and Surh Y.J. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 224 (2005) 171-184
69. 2 in human mesangial cells. Kidney Int 65 (2004) 798-810
70. 2 through up-regulation of cellular glutathione via different mechanisms. J Biol Chem (2006)
71. Hosoya T., Maruyama A., Kang M.I., Kawatani Y., Shibata T., Uchida K., et al. Differential responses of the Nrf2-Keap1 system to laminar and oscillatory shear stresses in endothelial cells. J Biol Chem 280 (2005) 27244-27250
72. Baeuerle P.A., and Baichwal V.R. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 65 (1997) 111-137
73. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18 (1999) 6853-6866
74. Hayden M.S., and Ghosh S. Signaling to NF-κB. Genes Dev 18 (2004) 2195-2224
75. Yang F., Tang E., Guan K., and Wang C.Y. IKKβ plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 170 (2003) 5630-5635
76. Sakurai H., Chiba H., Miyoshi H., Sugita T., and Toriumi W. IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274 (1999) 30353-30356
77. Bharti A.C., and Aggarwal B.B. Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem Pharmacol 64 (2002) 883-888
78. Gerritsen M.E., Williams A.J., Neish A.S., Moore S., Shi Y., and Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 94 (1997) 2927-2932
79. Zhong H., May M.J., Jimi E., and Ghosh S. The phosphorylation status of nuclear NF-κB determines its association with CBP/p300 or HDAC-1. Mol Cell 9 (2002) 625-636
80. Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4 (2002) E131-E136
81. 2 inhibits IL-1β-induced cyclooxygenase-2 expression in mesangial cells. Kidney Int 61 (2002) 1957-1967
82. 2, but not troglitazone, modulates IL-1β effects in human chondrocytes by inhibiting NF-κB and AP-1 activation pathways. FEBS Lett 501 (2001) 24-30
83. Simonin M.A., Bordji K., Boyault S., Bianchi A., Gouze E., Becuwe P., et al. PPAR-γ ligands modulate effects of LPS in stimulated rat synovial fibroblasts. Am J Physiol Cell Physiol 282 (2002) C125-C133
84. 2 inhibits expression of eNOS in human endothelial cells. Prostaglandins Other Lipid Mediat 74 (2004) 11-28
85. 2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-γ-independent mechanism. Cancer Res 64 (2004) 5162-5171
86. Darnell Jr. J.E. STATs and gene regulation. Science 277 (1997) 1630-1635
87. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3 (2002) 651-662
88. 2 on cytokine signaling in pancreatic β-cells. Am J Physiol Endocrinol Metab 286 (2004) E329-E336
89. 2, involves inhibition of the upstream Janus kinase/STAT1 signaling pathway. J Immunol 171 (2003) 979-988
90. Park E.J., Park S.Y., Joe E.H., and Jou I. 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol Chem 278 (2003) 14747-14752
91. 2. Rheumatology (Oxford) 44 (2005) 983-988
92. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
93. 2: the endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci USA 99 (2002) 7367-7372
94. 2 on proteasome. Biochemistry 42 (2003) 13960-13968
95. Moos P.J., Edes K., and Fitzpatrick F.A. Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc Natl Acad Sci USA 97 (2000) 9215-9220
96. Hainaut P., and Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res 53 (1993) 4469-4473
97. Jozkowicz A., Dulak J., Piatkowska E., Placha W., and Dembinska-Kiec A. Ligands of peroxisome proliferator-activated receptor-γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim Pol 47 (2000) 1147-1157
98. Inoue M., Itoh H., Tanaka T., Chun T.H., Doi K., Fukunaga Y., et al. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-γ. Arterioscler Thromb Vasc Biol 21 (2001) 560-566
99. Yamakawa K., Hosoi M., Koyama H., Tanaka S., Fukumoto S., Morii H., et al. Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 271 (2000) 571-574
100. 2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637. Int J Oncol 21 (2002) 915-920
101. Kimura H., Weisz A., Kurashima Y., Hashimoto K., Ogura T., D'Acquisto F., et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95 (2000) 189-197
102. Liu Y., Cox S.R., Morita T., and Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells Identification of a 5′ enhancer. Circ Res 77 (1995) 638-643
103. Hirota K., and Semenza G.L. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun 338 (2005) 610-616
104. Nikinmaa M., Pursiheimo S., and Soitamo A.J. Redox state regulates HIF-1α and its DNA binding and phosphorylation in salmonid cells. J Cell Sci 117 (2004) 3201-3216
105. Palmer L.A., Gaston B., and Johns R.A. Normoxic stabilization of hypoxia-inducible factor-1 expression and activity: redox-dependent effect of nitrogen oxides. Mol Pharmacol 58 (2000) 1197-1203
106. Huang L.E., Willmore W.G., Gu J., Goldberg M.A., and Bunn H.F. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide Implications for oxygen sensing and signalling. J Biol Chem 274 (1999) 9038-9044
107. Yasinska I.M., and Sumbayev V.V. S-nitrosation of Cys-800 of HIF-1α protein activates its interaction with p300 and stimulates its transcriptional activity. FEBS Lett 549 (2003) 105-109
108. Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K., et al. Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18 (1999) 1905-1914
109. Gu J., Milligan J., and Huang L.E. Molecular mechanism of hypoxia-inducible factor 1α -p300 interaction A leucine-rich interface regulated by a single cysteine. J Biol Chem 276 (2001) 3550-3554
110. Planaguma A., Claria J., Miquel R., Lopez-Parra M., Titos E., Masferrer J.L., et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARγ activation. FASEB J 19 (2005) 1120-1122
111. 2. J Biol Chem 274 (1999) 17042-17048
112. Qin C., Burghardt R., Smith R., Wormke M., Stewart J., and Safe S. Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells. Cancer Res 63 (2003) 958-964
113. Clay C.E., Namen A.M., Atsumi G., Willingham M.C., High K.P., Kute T.E., et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 20 (1999) 1905-1911
114. Huang H., Campbell S.C., Bedford D.F., Nelius T., Veliceasa D., Shroff E.H., et al. Peroxisome proliferator-activated receptor γ ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol Cancer Res 2 (2004) 541-550